A subset of high- Titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII

Blood

Volumn 127, Issue 16, 2016, Pages 2028-2034

  Eubanks, Joshua ^a   Baldwin, W Hunter ^b   Markovitz, Rebecca ^a   Parker, Ernest T ^b   Cox, Courtney ^b   Kempton, Christine L ^a,b   Meeks, Shannon L ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D4; MONOCLONAL ANTIBODY 2-54; MONOCLONAL ANTIBODY 2-76; MONOCLONAL ANTIBODY 4A4; MONOCLONAL ANTIBODY 4C7; MONOCLONAL ANTIBODY B25; MONOCLONAL ANTIBODY B94; MONOCLONAL ANTIBODY GMA 012; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; EPITOPE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CATALYST; CONTROLLED STUDY; EMBRYO; FEMALE; HEMOPHILIA; HEMOPHILIA A; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; TREATMENT RESPONSE; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMSTER; HEMORRHAGE; IMMUNOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CRICETINAE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY;

EID: 84965050089     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-670034     Document Type: Article

References (31)

1. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998;273(30):19049-19054.
2. Jenkins PV, Dill JL, Zhou Q, Fay PJ. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry. 2004;43(17):5094-5101.
3. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem. 1991;266(19):12481-12486.
4. Prescott R, Nakai H, Saenko EL, et al; Recombinate and Kogenate Study Groups. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997;89(10):3663-3671.
5. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60(5):1103-1109.
6. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood. 2007;110(13):4234-4242.
7. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost. 2007;5(3):512-519.
8. Markovitz RC, Healey JF, Parker ET, Meeks SL, Lollar P. The diversity of the immune response to the A2 domain of human factor VIII. Blood. 2013; 121(14):2785-2795.
9. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271(44): 27424-27431.
10. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood. 2008;112(4):1151-1153.
11. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost. 2009;7(4): 658-664.
12. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270(24): 14505-14509.
13. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood. 2000;95(2):564-568.
14. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood. 1998;92(10): 3701-3709.
15. Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol. 1993;222:128-143.
16. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem. 2002; 277(41):38345-38349.
17. Lollar P, Parker CG, Tracy RP. Molecular characterization of commercial porcine factor VIII concentrate. Blood. 1988;71(1):137-143.
18. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995;4(11): 2411-2423.
19. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
20. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood. 1996;88(9):3446-3450.
21. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(2):612.
22. Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost. 2006;4(10):2223-2229.
23. Cid AR, Calabuig M, Cortina V, et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with themutation and bleeding phenotype. Haemophilia. 2008;14(5):1049-1054.
24. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol. 1994; 87(4):846-848.
25. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie. 2010;30(4):207-211.
26. Tran DQ, Moss E, Murphy DA, Kempton CL. Mitral valve repair in a Jehovah's witness with haemophilia A with high- Titre inhibitor. Haemophilia. 2015;21(6):e523-e525.
27. Hay CR. Acquired haemophilia. Baillieres Clin Haematol. 1998;11(2):287-303.
28. Collins PW, Hirsch S, Baglin TP, et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007;109(5):1870-1877.
29. Negrier C. Inhibitors to factor VIII: Treatment of acute bleeds. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Oxford, United Kingdom: Blackwell Publishing Ltd.; 2005:80-85.
30. Luna-Ź aizar H, Esparza-Flores MA, Ĺopez-Guido B, Aguilar-Ĺopez LB, Cortés Alvarez CR, Jaloma- Cruz AR. Kinetics of factor VIII:C inhibitors and treatment response in severe hemophilia A patients. Int J Lab Hematol. 2009;31(6):673-682.
31. Doshi BS, Gangadharan B, Doering CB, Meeks SL. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PLoS One. 2012;7(10):e48172.